2025
P0442 Prevalence and Impact of E-cigarettes on Disease Outcomes in Patients with Inflammatory Bowel Disease
Almuhaya H, Alashkar R, Alsebaai D, Albadawi N, Almutairdi A, Attamimi M, Desai S, Al-Bawardy B. P0442 Prevalence and Impact of E-cigarettes on Disease Outcomes in Patients with Inflammatory Bowel Disease. Journal Of Crohn's And Colitis 2025, 19: i951-i951. DOI: 10.1093/ecco-jcc/jjae190.0616.Peer-Reviewed Original ResearchTraditional cigarette smokingPrevalence of EC useClinical outcomesCrohn's diseaseEC useAdvanced therapiesIBD patientsCigarette smokingUlcerative colitisElectronic cigarettesPenetrating diseaseComposite outcomeIBD-unclassifiedHistory of intestinal surgeryAssociated with male sexFollow-up durationImpact of e-cigarettesDiagnosis of IBDCross-sectional studyCigarette smoking historyInflammatory bowel diseaseNo significant differencePerianal diseaseIBD registrySurgical intervention
2024
STABILITY (Symptomatic Review during Biologic Therapy) of Inflammatory Bowel Disease Patients Receiving Infusion Therapy Improves Clinical Outcomes
Morgan K, Morris J, Cai Q, Kilgore P, Cvek U, Trutschl M, Lofton K, Mavuram M, Ramesh P, Dao N, Alhaque A, Alexander J. STABILITY (Symptomatic Review during Biologic Therapy) of Inflammatory Bowel Disease Patients Receiving Infusion Therapy Improves Clinical Outcomes. Pathophysiology 2024, 31: 398-407. PMID: 39189166, PMCID: PMC11348379, DOI: 10.3390/pathophysiology31030030.Peer-Reviewed Original ResearchInflammatory bowel disease patientsInflammatory bowel diseaseFemale IBD patientsMale CD patientsMale IBD patientsCD patientsUC patientsTherapy visitsIBD patientsDisease severityInfusion therapyFemale UC patientsMale UC patientsRetrospective chart reviewIBD-related symptomsPhysician-patient contactLow disease activityPhysician-patient interviewImprove patient outcomesFemale CD patientsCare gapsImproving clinical outcomesDiagnosis dateMedication changesChronic diseasesInflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia.
AlDhneem H, AlMutairdi A, Attamimi M, Mosli M, AlAmeel T, Al-Bawardy B. Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 260-265. PMID: 38841910, PMCID: PMC11379256, DOI: 10.4103/sjg.sjg_19_24.Peer-Reviewed Original ResearchInflammatory bowel diseaseGI fellowsElderly/frail patientsAssociated with higher confidenceExternal rotationInflammatory bowel disease knowledgePreventive health servicesMulticenter survey studyManagement of inflammatory bowel diseaseInflammatory bowel disease managementGastroenterology fellowsHealth servicesSaudi ArabiaFellows' confidenceDidactic sessionsMethods of trainingExtraintestinal manifestationsCounseling patientsIBD patientsBowel diseaseIBD managementPatientsPreference learning methodLow confidenceConfidenceClinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE
Fiske H, Ward C, Shah S, Holubar S, Al-Bawardy B, Barnes E, Binion D, Bohm M, Brand M, Clarke K, Cohen B, Cross R, Dueker J, Engels M, Farraye F, Fine S, Forster E, Gaidos J, Ginsburg P, Goyal A, Hanson J, Herfath H, Hull T, Kelly C, Lazarev M, Levy L, Melia J, Philpott J, Qazi T, Siegel C, Watson A, Wexner S, Williams E, Regueiro M. Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE. Crohn's & Colitis 360 2024, 6: otae022. PMID: 38720935, PMCID: PMC11078036, DOI: 10.1093/crocol/otae022.Peer-Reviewed Original ResearchInflammatory bowel diseaseReview of patient historyPresentation of inflammatory bowel diseaseInflammatory bowel disease patientsTreated with biologicsCost of patient careClinical management implicationsReassessment of treatmentIBD specialistsClinical responseMedication-inducedIBD patientsPrescribed steroidsPatient careEndoscopic biopsyTherapeutic workupMultidisciplinary managementIBD casesBalloon enteroscopyAdverse eventsDifferential diagnosisDisease mimicsDiverse presentationsPatient historyBowel diseaseEpstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia
Al-Bawardy B, Alfadley A, Almousallam M, AlShathri S, Aboueissa M, Alsulaiman A, Attamimi M, AlMutairdi A. Epstein-Barr virus seroprevalence among inflammatory bowel disease patients in Saudi Arabia. Saudi Journal Of Gastroenterology 2024, 30: 168-172. PMID: 38358251, PMCID: PMC11198918, DOI: 10.4103/sjg.sjg_380_23.Peer-Reviewed Original ResearchSeroprevalence of EBVEpstein-Barr virusInflammatory bowel diseaseYears of ageEBV seroprevalenceEpstein-Barr virus statusCohort of IBD patientsDiagnosis of inflammatory bowel diseaseInflammatory bowel disease patientsRetrospective chart reviewFollow-up timeRate of seroconversionNon-exposureEBV seroconversionThiopurine therapyEBV-seropositiveNegative patientsTertiary centerIBD patientsPrimary outcomeSecondary outcomesBowel diseasePatientsVirus seroprevalenceDisease patients
2023
S1000 Exploring the Influence of COVID-19 Treatment on Real-World Outcomes in IBD Patients: A Comprehensive Analysis
Sahyoun L, McMillan C, Fetene J, Protiva P, Al-Bawardy B, Gaidos J, Proctor D. S1000 Exploring the Influence of COVID-19 Treatment on Real-World Outcomes in IBD Patients: A Comprehensive Analysis. The American Journal Of Gastroenterology 2023, 118: s757-s757. DOI: 10.14309/01.ajg.0000953640.32433.d2.Peer-Reviewed Original ResearchS947 Why IBD Patients Aren’t Eating ‘an Apple a Day:’ Understanding Dietary Fiber Avoidance in Inflammatory Bowel Disease
Vasudevan J, Damianos J, DiVincenzo C, Gaidos J, Burgermaster M, Feagins L. S947 Why IBD Patients Aren’t Eating ‘an Apple a Day:’ Understanding Dietary Fiber Avoidance in Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2023, 118: s710-s711. DOI: 10.14309/01.ajg.0000953428.77556.69.Peer-Reviewed Original ResearchCorticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease
Long M, Parlett L, Lewis J, Haynes K, Adimadhyam S, Hou L, Wolfe A, Toh S, Burris J, Dorand J, Kappelman M. Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2023, 30: 1345-1352. PMID: 37611117, DOI: 10.1093/ibd/izad176.Peer-Reviewed Original ResearchInflammatory bowel diseaseAnti-tumor necrosis factor α therapyCOVID-19 complicationsMechanical ventilationBowel diseaseΑ therapyCOVID-19Users of corticosteroidsRetrospective cohort studyIncidence of hospitalizationCOVID-19 hospitalizationOutcomes of interestIBD medicationsIBD patientsOutpatient deathsCohort studyInpatient deathMedication utilizationMore hospitalizationsDecreased riskImmunosuppressed individualsMean ageTreatment codesLarge cohortCorticosteroidsOutcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssays
2022
A Practical Approach to IBD Care in the Pregnant Patient
Sahyoun L, Gaidos J. A Practical Approach to IBD Care in the Pregnant Patient. Current Gastroenterology Reports 2022, 24: 201-209. PMID: 36422770, DOI: 10.1007/s11894-022-00856-3.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseManagement of IBDPrior inflammatory bowel diseaseNew IBD therapiesNew biologic agentsPouch-anal anastomosisSimilar success ratesPurpose of ReviewAsIBD careIBD patientsIBD therapyActive diseaseDisease remissionFetal outcomesIBD treatmentPregnant patientsIBD populationPreconception counselingPregnancy outcomesBiologic agentsBowel diseasePeripartum periodMedication safetyPrevious guidelinesPregnancyEffect of obesity on vedolizumab response in inflammatory bowel disease
Levine LJ, Gaidos JKJ, Proctor DD, Viana AV, Al-Bawardy B. Effect of obesity on vedolizumab response in inflammatory bowel disease. Annals Of Gastroenterology 2022, 35: 275-280. PMID: 35599926, PMCID: PMC9062841, DOI: 10.20524/aog.2022.0699.Peer-Reviewed Original ResearchBody mass indexInflammatory bowel diseaseSteroid-free clinical remissionNon-obese groupC-reactive proteinObese groupCRP normalizationEndoscopic remissionIBD patientsBowel diseaseDose escalationNormal serum C-reactive proteinMedian body mass indexSerum C-reactive proteinHigher Body Mass IndexEndoscopic remission ratesEffect of obesityVedolizumab discontinuationVedolizumab levelsClinical remissionMedian followRemission rateSecondary outcomesMedian agePrimary outcome
2021
The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services
Hussain N, Proctor D, Al-Bawardy B. The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services. Crohn's & Colitis 360 2021, 3: otab067. PMID: 36777277, PMCID: PMC9802036, DOI: 10.1093/crocol/otab067.Peer-Reviewed Original ResearchInflammatory bowel diseaseClinic BIBD clinicHerpes zosterClinic AVaccination servicesSite vaccinationVaccine discussionsInflammatory bowel disease clinicHepatitis B vaccinationVaccine-preventable diseasesLow vaccination ratesCompletion ratesB vaccinationIBD patientsIBD physiciansVaccine completionBowel diseaseDisease clinicClinic 1Retrospective studyVaccination ratesDiscussion rateComprehensive careImmunization ratesClinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases
Saberzadeh-Ardestani B, Anushiravani A, Mansour-Ghanaei F, Fakheri H, Vahedi H, Sheikhesmaeili F, Yazdanbod A, Moosavy S, Vosoghinia H, Maleki I, Nasseri-Moghaddam S, Khosravi B, Malekzadeh M, Kasaeian A, Alatab S, Sadeghi A, Kolahdoozan S, Rayatpisheh M, Sima A, Malekzadeh R. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases. Inflammatory Bowel Diseases 2021, 28: 1004-1011. PMID: 34417824, DOI: 10.1093/ibd/izab202.Peer-Reviewed Original ResearchConceptsIBD-related surgeryNational matched case-control studyFamily historyHistory of colon cancerManitoba IBD IndexFamilial IBD patientsInflammatory bowel diseaseClinical phenotypeFamilial casesFamily history of IBDIBD patientsCase-control studyHistory of IBDExtraintestinal manifestationsDisease course of inflammatory bowel diseaseAggressive phenotypeDisease courseColon cancerBowel diseaseFamilial UCSporadic casesEmergency visitsIBD medicationsAnti-TNF useCourse of inflammatory bowel diseaseTHE CLINICAL FEATURES AND PROGNOSTIC VALUE OF INFLAMMATORY POLYPS IN THE J POUCH OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY PROCTOCOLECTOMY WITH ILEAL POUCH-ANAL ANASTOMOSIS
Akiyama S, Ollech J, Rai V, Yi Y, Traboulsi C, Glick L, Runde J, Cohen R, Hurst R, Hyman N, Dalal S, Sakuraba A, Pekow J, Rubin D. THE CLINICAL FEATURES AND PROGNOSTIC VALUE OF INFLAMMATORY POLYPS IN THE J POUCH OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY PROCTOCOLECTOMY WITH ILEAL POUCH-ANAL ANASTOMOSIS. Inflammatory Bowel Diseases 2021, 27: s45-s45. DOI: 10.1093/ibd/izaa347.109.Peer-Reviewed Original ResearchIleal pouch-anal anastomosisInflammatory bowel diseaseAnti-TNF drugsInflammatory polypsPouch-anal anastomosisKaplan-Meier curvesJ-pouchIBD patientsPouch excisionEndoscopic findingsBowel diseaseRectal cuffDistal pouchRetrospective single-center studyCommon anatomical locationSingle-center studyLog-rank testErythema/edemaLogistic regression analysisDifferent anatomic areasRefractory colitisChronic pouchitisBackground PatientsTotal proctocolectomyIndependent predictorsTHE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS
Li M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Inflammatory Bowel Diseases 2021, 27: s45-s46. DOI: 10.1093/ibd/izaa347.110.Peer-Reviewed Original ResearchInflammatory bowel diseaseBiologic agentsAdverse eventsSmall molecule therapiesClinical remissionMucosal healingBowel diseaseConcomitant cirrhosisConcomitant corticosteroid therapyDifferent biologic agentsPrimary sclerosing cholangitisQuarter of patientsCohort of patientsEffectiveness of biologicsSmall molecule agentsConcomitant thiopurinesCorticosteroid therapyIBD patientsIBD therapyCertolizumab pegolSclerosing cholangitisAdult patientsBiologic therapyInfusion reactionsSecondary outcomesAssessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology
Karpin J, Rodriguez T, Traboulsi C, Rai V, Gibbons R, Rubin D. Assessment of Comorbid Depression and Anxiety in Inflammatory Bowel Disease Using Adaptive Testing Technology. Crohn's & Colitis 360 2021, 3: otaa095. PMID: 34746788, PMCID: PMC8570563, DOI: 10.1093/crocol/otaa095.Peer-Reviewed Original ResearchInflammatory bowel diseaseBowel diseaseExact testActive inflammatory bowel diseaseClinical remission statusNegative CRP valuesMental health screeningPearson's chi-square testFisher's exact testMental health conditionsChi-square testCAT-MHIBD clinicIBD patientsPositive CRPUndiagnosed anxietyClinical remissionDisease activityIBD populationPatient characteristicsConsecutive patientsCRP valuesMultivariable analysisSignificant positive associationRemission statusRoles of microRNAs in inflammatory bowel disease
Jung H, Kim J, Lee K, Tizaoui K, Terrazzino S, Cargnin S, Smith L, Koyanagi A, Jacob L, Li H, Hong S, Yon D, Lee S, Kim M, Wasuwanich P, Karnsakul W, Shin J, Kronbichler A. Roles of microRNAs in inflammatory bowel disease. International Journal Of Biological Sciences 2021, 17: 2112-2123. PMID: 34131410, PMCID: PMC8193269, DOI: 10.7150/ijbs.59904.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseRegulate gene expressionBowel diseaseSamples of IBD patientsTreatment of inflammatory bowel diseasePathogenesis of inflammatory bowel diseaseRNA moleculesSerum samples of IBD patientsChronic inflammatory diseaseTreat inflammatory bowel diseaseGene expressionHost immune responseIntestinal bacteriaQuality of life of patientsSignaling pathwayIntestinal barrierIntestinal epitheliumLife of patientsGastrointestinal symptomsIntracolonic administrationPathophysiological mechanismsIBD patientsInflammatory diseasesImmune responseColon tissues
2020
A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience-Study Protocol
Anushiravani A, Vahedi H, Fakheri H, Mansour-ghanaei F, Maleki I, Nasseri-Moghaddam S, Vosoghinia H, Ghadir M, Hormati A, Aminisani N, Radmard A, Khosravi B, Saberzadeh-Ardestani B, Malekzadeh M, Alatab S, Sadeghi A, Salahi S, Malekzadeh R, Sima A. A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience-Study Protocol. Middle East Journal Of Digestive Diseases 2020, 12: 238-245. PMID: 33564380, PMCID: PMC7859612, DOI: 10.34172/mejdd.2020.188.Peer-Reviewed Original ResearchInflammatory bowel disease patientsDistribute educational materialsInflammatory bowel diseaseHealth care infrastructureIBD patientsFollow-upCare infrastructureRisk of COVID-19 infectionChronic diseasesPhone callsOutpatient clinicCOVID-19Educational materialsHotline callsPatient follow-upIranian RegistryBowel diseaseCOVID-19 infectionHospital guidanceCareManagement of patientsCOVID-19 pandemicPhysiciansIranian patientsCOVID-19 outbreakPrimary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation
Aranake-Chrisinger J, Dassopoulos T, Yan Y, Nalbantoglu I. Primary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation. World Journal Of Gastroenterology 2020, 26: 4126-4139. PMID: 32821074, PMCID: PMC7403798, DOI: 10.3748/wjg.v26.i28.4126.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseOrthotopic liver transplantationPSC-IBD patientsUlcerative colitisCrohn's diseasePSC-UCLiver transplantationHistologic featuresLeft colonPSC-UC patientsPrimary sclerosing cholangitisRight-sided diseaseWarrants clinical attentionDifferent disease phenotypesIBD durationIBD patientsPSC patientsSclerosing cholangitisUC patientsActive inflammationRectal involvementBowel diseaseClinical featuresPSC diagnosisLess steroidsSu1867 BIG DATA ANALYTICS DEMONSTRATE A NOVEL, UNEXPECTED ASSOCIATION OF LOW SERUM IGG4 ANTIBODIES WITH INCREASED DISEASE SEVERITY IN 20% OF IBD PATIENTS
Koutroumpakis F, Phillips A, Yadav D, Ahsan M, Rivers C, Machicado J, Tan X, Proksell S, Johnston E, Dueker J, Din H, Jana H, Tang G, Babichenko D, Barrie A, Hartman D, Konnikova L, Dunn M, Binion D. Su1867 BIG DATA ANALYTICS DEMONSTRATE A NOVEL, UNEXPECTED ASSOCIATION OF LOW SERUM IGG4 ANTIBODIES WITH INCREASED DISEASE SEVERITY IN 20% OF IBD PATIENTS. Gastroenterology 2020, 158: s-681-s-682. DOI: 10.1016/s0016-5085(20)32394-5.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply